PCSK9抑制剂的降脂治疗研究进展  

Research Progress of PCSK9 Inhibitors in Lipid-Lowering Therapy

作　　者：宫喜 魏子秀[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁市第一人民医院心内科,山东 济宁

出　　处：《临床医学进展》2023年第8期13414-13419,共6页Advances in Clinical Medicine

摘　　要：低密度脂蛋白胆固醇(LDL-C)水平升高是冠状动脉粥样硬化性心血管疾病(ASCVD)的重要危险因素。他汀类药物仍是当前降脂治疗的基石,经过他汀类药物治疗后,仍有部分高危患者无法降至目标LDL-C水平。前蛋白转化酶枯草杆菌蛋白酶Kexin-9 (PCSK9)是一种参与LDL-C受体降解过程的蛋白酶,已成为降脂治疗的关键靶点。PCSK9抑制剂可通过抑制PCSK9加速LDL-C清除,为降脂治疗提供了新思路,其疗效及安全性已在临床试验中得到证实。本综述对PCSK9作用机制及PCSK9抑制剂临床疗效进行了总结。Elevated low-density lipoprotein cholesterol (LDL-C) level is an important risk factor for atheroscle-rotic cardiovascular disease (ASCVD). Statins are still the cornerstone of current lipid-lowering therapy, and some high-risk patients still cannot reach the target LDL-C level after statin therapy. Proprotein convertase subtilisin kexin type 9 (PCSK9) is a protease involved in the degradation of LDL-C receptors and has become a key target for lipid-lowering therapy. PCSK9 inhibitors can ac-celerate LDL-C clearance by inhibiting PCSK9, and provides a new idea for lipid-lowering therapy, and its efficacy and safety have been confirmed in clinical trials. This review summarizes the mechanism of action of PCSK9 and the clinical efficacy of PCSK9 inhibitors.

关 键 词：PCSK9抑制剂 低密度脂蛋白胆固醇 依洛尤单抗 阿利西尤单抗 

分 类 号：R54[医药卫生—心血管疾病]